The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany

Kohli, Michele; Maschio, Michael; Cartier, Shannon; Mould, J.F.; Fricke, Frank-Ulrich

doi:10.3390/vaccines10091386

Cited by 9 publications

(20 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, aQIV fell below the Spanish cost-effectiveness threshold in this study [ 21 ]. The findings of both modeled comparisons—aQIV vs. HD-QIV and aQIV vs. QIVr—are consistent with cost-effectiveness studies of aQIV conducted in Europe and Latin America [ 45 , 46 , 47 , 48 ]. A study in Germany used a compartmental transmission model to predict the number of medically attended infections among adults ≥65 years vaccinated with aQIV or HD-QIV and assumed the rVE range of –2.5% to 8.9% for aQIV vs. HD-QIV, based on data from the meta-analysis of aTIV and HD-TIV comparisons [ 44 , 45 ].…”

Section: Discussionsupporting

confidence: 76%

“…The findings of both modeled comparisons—aQIV vs. HD-QIV and aQIV vs. QIVr—are consistent with cost-effectiveness studies of aQIV conducted in Europe and Latin America [ 45 , 46 , 47 , 48 ]. A study in Germany used a compartmental transmission model to predict the number of medically attended infections among adults ≥65 years vaccinated with aQIV or HD-QIV and assumed the rVE range of –2.5% to 8.9% for aQIV vs. HD-QIV, based on data from the meta-analysis of aTIV and HD-TIV comparisons [ 44 , 45 ]. In different modeling scenarios conducted based on influenza severity and the rVE range of –2.5% to 8.9% for aQIV vs. HD-QIV, aQIV was consistently shown to be cost saving because the unit cost of aQIV (EUR 19.21) was less than half that of HD-QIV (EUR 40.55), while vaccine effectiveness was similar.…”

Section: Discussionsupporting

confidence: 76%

“…In different modeling scenarios conducted based on influenza severity and the rVE range of –2.5% to 8.9% for aQIV vs. HD-QIV, aQIV was consistently shown to be cost saving because the unit cost of aQIV (EUR 19.21) was less than half that of HD-QIV (EUR 40.55), while vaccine effectiveness was similar. Even in the scenario where the rVE was –2.5% (favoring HD-QIV over aQIV), aQIV was more cost effective [ 45 ]. The same authors conducted a modeling study in the United Kingdom before HD-QIV was available there.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain

Ruiz-Aragón¹,

Márquez-Peláez

2023

Vaccines

View full text Add to dashboard Cite

Influenza infections impose a high burden of morbidity and mortality among older adults, at great cost to individuals and society. Enhanced influenza vaccines, which contain either an immune adjuvant or higher than normal doses of influenza virus antigens, are recommended for older adults. We used a health economics model to evaluate the cost effectiveness in Spain of a recently licensed recombinant quadrivalent influenza vaccine (QIVr), which contains three times the standard dose of influenza virus hemagglutinin but no neuraminidase, compared with an MF59-adjuvanted quadrivalent influenza vaccine (aQIV). Based on current tender prices in Spain and a conservative assumption that QIVr is 10.7% relatively more effective than aQIV, the incremental cost-effectiveness ratio (ICER) for QIVr was EUR 101,612.41 per quality-adjusted life year (QALY) gained. To meet the Spanish willingness-to-pay threshold of EUR 25,000 per QALY gained, QIVr would need to be 34.1% relatively more effective than aQIV. In a probabilistic sensitivity analysis conducted to confirm the robustness of the analysis, 99.7% of simulations for QIVr were higher than the willingness-to-pay curve. These findings suggest that QIVr is not currently a cost-effective influenza vaccine option relative to aQIV for older persons living in Spain.

show abstract

Section: Discussionsupporting

confidence: 76%

Section: Discussionsupporting

confidence: 76%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain

Ruiz-Aragón¹,

Márquez-Peláez

2023

Vaccines

View full text Add to dashboard Cite

show abstract

“…To our knowledge, this is the first evaluation of the cost-effectiveness of an adjuvanted QIV for older adults in Ireland. Previous studies in other countries have also shown aQIV to be more cost-effective for use in older adults compared with standard-dose QIVs [ 18 , 19 , 21 , 28 , 42 ]. While the degree of cost-effectiveness varied with the vaccine price, cost benefits were mainly driven by the higher vaccine effectiveness of aQIV in this age group.…”

Section: Discussionmentioning

confidence: 99%

Cost-Effectiveness of the Use of Adjuvanted Quadrivalent Seasonal Influenza Vaccine in Older Adults in Ireland

2023

Self Cite

View full text Add to dashboard Cite

Background: Enhanced vaccines (e.g., containing adjuvants) have shown increased immunogenicity and effectiveness in older adults, who often respond sub-optimally to conventional influenza vaccines. In this study, we evaluated the cost-effectiveness of an inactivated, seasonal, MF59-adjuvanted quadrivalent influenza vaccine (aQIV) for use in adults ≥ 65 years in Ireland. Methods: A published dynamic influenza model incorporating social contact, population immunity, and epidemiological data was used to assess the cost-effectiveness of aQIV in adults ≥ 65 years of age compared with a non-adjuvanted QIV. Sensitivity analysis was performed for influenza incidence, relative vaccine effectiveness, excess mortality, and the impact on bed occupancy from co-circulating influenza and COVID-19. Results: The use of aQIV resulted in discounted incremental cost-effectiveness ratios (ICERs) of EUR 2420/quality-adjusted life years (QALYs) and EUR 12,970/QALY from societal and payer perspectives, respectively, both of which are below the cost-effectiveness threshold of EUR 45,000/QALY. Sensitivity analysis showed that aQIV was effective in most scenarios, except when relative vaccine effectiveness compared to QIV was below 3%, and resulted in a modest reduction in excess bed occupancy. Conclusion: The use of aQIV for adults ≥ 65 years old in Ireland was shown to be highly cost-effective from both payer and societal perspectives.

show abstract

“…In an analysis from Germany, adjuvant and high-dose influenza vaccines achieved similar clinically results (hospitalisations, deaths, etc . ), but the adjuvant vaccine was more cost saving compared to high-dose vaccine [ 72 ]. None of the mentioned studies suggested any clinically relevant changes in safety beyond what is known.…”

Section: Influenza Vaccinementioning

confidence: 99%

The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus

Simon,

Joean,

Welte

et al. 2023

Eur Respir Rev

View full text Add to dashboard Cite

Exacerbations of COPD are associated with worsening of the airflow obstruction, hospitalisation, reduced quality of life, disease progression and death. At least 70% of COPD exacerbations are infectious in origin, with respiratory viruses identified in approximately 30% of cases. Despite long-standing recommendations to vaccinate patients with COPD, vaccination rates remain suboptimal in this population.Streptococcus pneumoniaeis one of the leading morbidity and mortality causes of lower respiratory tract infections. The Food and Drug Administration recently approved pneumococcal conjugate vaccines that showed strong immunogenicity against all 20 included serotypes. Influenza is the second most common virus linked to severe acute exacerbations of COPD. The variable vaccine efficacy across virus subtypes and the impaired immune response are significant drawbacks in the influenza vaccination strategy. High-dose and adjuvant vaccines are new approaches to tackle these problems. Respiratory syncytial virus is another virus known to cause acute exacerbations of COPD. The vaccine candidate RSVPreF3 is the first authorised for the prevention of RSV in adults ≥60 years and might help to reduce acute exacerbations of COPD. The 2023 Global Initiative for Chronic Lung Disease report recommends zoster vaccination to protect against shingles for people with COPD over 50 years.

show abstract

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany

Cited by 9 publications

References 42 publications

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain

Cost-Effectiveness of the Use of Adjuvanted Quadrivalent Seasonal Influenza Vaccine in Older Adults in Ireland

The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus

Contact Info

Product

Resources

About